{"filings":[{"id":759196,"accession_number":"0001599298-26-000043","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2026-06-01T10:57:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ivonescimab: 70.8% ORR in mCRC Phase II; HARMONi-6 OS HR 0.66 vs tislelizumab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase II AK112-206 in 1L mCRC: ORR 70.8%, DCR 100.0% in evaluable patients (n=48); 9-month PFS rate 76.1% for 20 mg/kg arm.","HARMONi-6 Phase III in squamous NSCLC: OS HR 0.66 (p=0.0017) vs tislelizumab + chemo; 24-month OS rates 64.7% vs 48.6%.","Ivonescimab + chemo reduced risk of death by 34% vs tislelizumab; first Phase III to show significant OS benefit over anti-PD-1 + chemo in 1L NSCLC.","Safety profiles manageable; no new safety signals; TRAEs leading to discontinuation in HARMONi-6: 5.3% vs 4.5%.","Data presented at ASCO 2026; HARMONi-6 results simultaneously published in The Lancet; Summit to host conference call June 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93988,"accession_number":"0001599298-26-000037","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Summit Q1 net loss $189.4M, cash $598.7M; ivonescimab OS data at ASCO plenary","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $189.4M ($0.24/sh) vs $62.9M ($0.09/sh) YoY; non-GAAP net loss $116.6M ($0.15/sh).","Cash and short-term investments $598.7M, down $114.7M from Dec 2025; cash burn funds ivonescimab trials.","HARMONi-6 (squamous NSCLC in China) OS data to be presented at ASCO 2026 plenary as late-breaking abstract.","HARMONi-3 squamous final PFS expected H2 2026; interim PFS cleared by iDMC, study continues blinded.","BLA for ivonescimab in EGFR-mutated NSCLC accepted; PDUFA date Nov 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106017,"accession_number":"0001599298-26-000014","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit FY25 GAAP net loss $1.08B, BLA accepted with PDUFA Nov 14, HARMONi-3 interim PFS Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $1,079.6M ($1.44/sh) vs $221.3M ($0.31/sh) FY24; non-GAAP net loss $347.2M ($0.46/sh).","Cash and equivalents $713.4M at Dec 31, 2025, up from $412.3M at Dec 31, 2024.","FDA accepted BLA for ivonescimab+chemo in EGFR-mutated NSCLC; PDUFA goal date Nov 14, 2026.","HARMONi-3 squamous cohort screening complete; interim PFS analysis planned Q2 2026; final PFS H2 2026.","New Phase III ILLUMINE study (GORTEC) in HNSCC to initiate; first patient expected early Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106016,"accession_number":"0001599298-26-000006","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Summit Therapeutics BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA; PDUFA Nov 14, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for ivonescimab + chemotherapy in EGFR-mutated non-squamous NSCLC post-TKI therapy.","PDUFA goal action date set for November 14, 2026.","BLA submission based on Phase III HARMONi trial results.","Over 14,000 U.S. patients eligible for treatment annually in this setting.","FDA plans full review including mid-cycle and wrap-up meetings before PDUFA date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106015,"accession_number":"0001599298-26-000004","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit submits BLA for ivonescimab in EGFRm NSCLC; $710M cash; GSK collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BLA submitted to FDA for ivonescimab + chemo in 2L+ EGFR-mutated NSCLC based on Phase III HARMONi; FDA decision expected Q4 2026.","Preliminary cash, cash equivalents, and short-term investments of ~$710M as of Dec 31, 2025.","Clinical collaboration with GSK to evaluate ivonescimab + risvutatug rezetecan (B7-H3 ADC) across solid tumors; dosing expected mid-2026.","Over 14,000 patients in the US annually eligible for 2L+ treatment of EGFRm NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122309,"accession_number":"0001599298-25-000166","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ivonescimab + chemo shows OS benefit in EGFRm NSCLC; HR 0.74 in HARMONi-A final analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final OS analysis: ivonescimab+chemo vs chemo achieved HR 0.74 (95% CI: 0.58-0.95, p=0.019); median OS 16.8 vs 14.1 months.","First Phase III study of ivonescimab to show statistically significant OS benefit; prior HARMONi showed PFS benefit.","Over 40,000 patients treated with ivonescimab in China in clinical/commercial settings.","Safety manageable: TRAE discontinuation 11.2% vs 6.2%; no additional TRAE deaths vs chemo alone.","Global HARMONi study subsequent OS analysis: HR 0.78 (nominal p=0.0332) consistent with primary HR 0.79."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122308,"accession_number":"0001193125-25-245790","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics raises $500M in private placement at $18.74/share; insiders invest $282M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $500M gross and net proceeds from sale of 26.68M shares at $18.74 each, the closing price on Oct 21, 2025.","Insiders including Duggan, Zanganeh, Soni, Anand contributed $272M; Akeso added $10M, total insider investment $282M.","Proceeds will fund clinical development of ivonescimab and general corporate purposes.","Closing expected on or before October 28, 2025, subject to customary conditions.","Shares issued in a private placement exempt from registration; resale registration to be filed by Dec 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122307,"accession_number":"0001599298-25-000156","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Summit plans BLA for ivonescimab in Q4 2025; HARMONi-6 meets endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans to submit BLA for ivonescimab plus chemotherapy in EGFRm NSCLC in Q4 2025 based on HARMONi study.","HARMONi-6: ivonescimab + chemo reduced risk of progression/death by 40% vs tislelizumab+chemo in 1L squamous NSCLC (HR=0.60, p<0.0001).","HARMONi-3 split into squamous and non-squamous analyses; squamous enrollment completion expected H1 2026, data H2 2026.","New global Phase III HARMONi-GI3 in 1L CRC initiated; targets 600 patients, PFS primary endpoint.","Q3 2025 GAAP net loss $231.8M ($0.31/sh), non-GAAP net loss $101.0M ($0.13/sh); cash $238.6M at Sept 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139007,"accession_number":"0001599298-25-000137","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ivonescimab HARMONi trial shows improved OS trend in longer follow-up; North American HR=0.70","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Longer-term follow-up of Western patients: OS HR=0.78 (nominal p=0.0332); median OS 16.8 vs 14.0 months.","North American patients: median OS not reached for ivonescimab vs 14.0 months for placebo (HR=0.70).","Primary PFS analysis showed HR=0.52 (p<0.00001); median PFS 6.8 vs 4.4 months.","Overall response rate higher with ivonescimab (45% vs 34%); median duration of response 7.6 vs 4.2 months.","Safety profile manageable; TRAEs leading to discontinuation 7.3% (ivonescimab) vs 5.0% (placebo)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139006,"accession_number":"0001599298-25-000128","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ivonescimab HARMONi PFS HR 0.52, NMPA approval; Summit Q2 net loss $565.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["HARMONi PFS HR 0.52 (p<0.00001); OS trend HR 0.79 (p=0.057); BLA filing planned.","Ivonescimab monotherapy approved by NMPA for 1L PD-L1 positive advanced NSCLC in China.","HARMONi-6: ivonescimab + chemo superior to tislelizumab + chemo in 1L squamous NSCLC.","Cash & equivalents $297.9M (down from $412.3M); ATM offering of up to $360M.","GAAP net loss $565.7M ($0.76/sh); non-GAAP $86.9M ($0.12/sh); stock modification $466.6M non-cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139005,"accession_number":"0001193125-25-178022","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Summit Therapeutics expands ATM offering capacity by $360M to total $450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased ATM equity offering capacity by $360M; total authorized up to $450M under agreement with J.P. Morgan.","As of Aug 11, 2025, approximately $45.8M remained available for sale under the prior $90M facility.","New prospectus supplement filed Aug 11, 2025; terms unchanged (3% commission, at-the-market sales).","Company retains discretion; no obligation to sell any shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156512,"accession_number":"0001599298-25-000120","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Summit Therapeutics sub-subleases 36,406 sq ft Palo Alto office; ~$2.8M annual rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sub-sublease for 36,406 sq ft in Palo Alto, CA, effective June 16, 2025, starting Jan 1, 2026, expiring Oct 28, 2033.","Annual lease payments average ~$2.8M; term spans nearly 8 years from commencement.","Agreement conditioned on consent of landlord and sublandlord; will be filed as exhibit to Q2 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156511,"accession_number":"0001599298-25-000116","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Summit Therapeutics stockholders approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected (Duggan, Zanganeh, Soni, Clark, Booth, Cesano, Xia, Ronaghi, Huber) with >98% support.","Ratification of PwC as independent auditor for FY2025 approved: 653,328,708 for, 195,007 against, 233,629 abstain.","Non-binding say-on-pay resolution approved: 607,320,353 for, 16,607,648 against, 177,556 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156510,"accession_number":"0001599298-25-000099","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Summit's ivonescimab meets PFS endpoint in global Phase III HARMONi; OS trend positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ivonescimab + chemo reduced risk of progression or death by 48% vs chemo alone (HR 0.52; p<0.00001).","Overall survival showed positive trend (HR 0.79; p=0.057), not statistically significant.","No new safety signals; Grade 3+ TEAEs 56.9% ivonescimab arm vs 50.0% control.","Summit plans to file BLA with FDA but notes FDA requires statistically significant OS benefit.","Consistent PFS benefit observed across Asia and ex-Asia (including North America) sub-populations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156509,"accession_number":"0001599298-25-000088","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics Q1 net loss widens to $62.9M; ivonescimab gets second China approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $62.9M ($0.09/share) vs $43.5M ($0.06) in Q1 2024; R&D expenses rose to $51.2M.","Cash and investments $361.3M at Mar 31, 2025 vs $412.3M at Dec 31, 2024; non-GAAP op expenses $55.7M.","Ivonescimab showed statistically significant PFS superiority vs tislelizumab in HARMONi-6 trial (squamous NSCLC).","China NMPA approved ivonescimab for second indication (1L NSCLC with PD-L1+); interim OS HR=0.777.","Appointed Robert LaCaze as CCO; enrollment ongoing in HARMONi-3 and HARMONi-7; HARMONi topline expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156508,"accession_number":"0001599298-25-000066","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Summit: Ivonescimab gets second NMPA approval in China; OS hazard ratio 0.777","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NMPA approved ivonescimab for front-line PD-L1+ advanced NSCLC based on HARMONi-2 Phase III trial.","Interim OS analysis showed hazard ratio 0.777 (22% reduction in risk of death) at 39% data maturity.","Primary endpoint PFS previously showed HR 0.51 (p<0.0001) favoring ivonescimab over pembrolizumab.","Summit is enrolling HARMONi-7, a multiregional Phase III trial of ivonescimab vs pembrolizumab in same population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156507,"accession_number":"0001599298-25-000064","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ivonescimab + chemo beats tislelizumab + chemo in Phase III squamous NSCLC trial (HARMONi-6)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint PFS met: statistically significant and clinically meaningful improvement by BICR versus tislelizumab combo.","PFS benefit observed in both PD-L1 positive and PD-L1 negative tumors.","No new safety signals identified; full data set to be presented at upcoming medical conference.","Second ivonescimab Phase III to show superiority over PD-(L)1 therapy (after HARMONi-2 in PD-L1+ monotherapy).","Summit enrolling HARMONi-3 global Phase III vs pembrolizumab combo in 1L metastatic NSCLC with registrational intent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174938,"accession_number":"0001599298-25-000044","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics reports FY2024 net loss $221.3M; HARMONi enrollment complete, data mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & short-term investments $412.3M at Dec 31, 2024, up from $186.2M at Dec 31, 2023.","GAAP net loss $221.3M ($0.31/share) vs $614.9M ($0.99/share) prior year.","GAAP R&D expense $150.8M vs $59.4M prior year, driven by ivonescimab development.","HARMONi Phase III trial enrollment complete; top-line data expected mid-2025; FDA Fast Track granted.","Pfizer collaboration to evaluate ivonescimab with vedotin ADCs in solid tumors; studies start mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174937,"accession_number":"0001599298-25-000038","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Summit Therapeutics discloses ~$412M cash balance, awards $540K bonuses to CEO/CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents, and short-term investments ~$412M as of Dec 31, 2024, including $31.8M loan repayment.","CEO Dr. Zanganeh and CFO Manmeet Soni each granted $540K cash bonus for FY2024, payable Q1 2025; no bonus in FY2023.","Base salaries for both officers increase from $600K to $618K, effective February 1, 2025.","Cash balance is preliminary and subject to year-end closing adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174936,"accession_number":"0001599298-25-000034","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics reports preliminary cash ≥$410M as of Dec 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents, and short-term investments at least $410M.","Includes repayment of $31.8M related party loan (principal + interest) previously outstanding.","Amount is preliminary and subject to completion of year-end financial closing procedures.","Company presenting at J.P. Morgan Healthcare Conference on January 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191900,"accession_number":"0001599298-24-000156","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit reports Q3 net loss $56.3M; ivonescimab HARMONi-2 shows 49% risk reduction vs Keytruda","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $487M (vs $186.2M Dec 2023) after $235M private financing in Sep 2024.","GAAP net loss $56.3M ($0.08/share) vs $21.2M ($0.03/share) in Q3 2023; R&D spend $37.7M.","Ivonescimab in HARMONi-2 (NSCLC) reduced disease progression/death by 49% vs pembrolizumab (HR 0.51; p<0.0001).","HARMONi (2L+ EGFRm) enrollment complete; topline mid-2025. HARMONi-3 to expand to non-squamous; HARMONi-7 to start early 2025.","Phase II data at ESMO/WCLC showed 71.8% MPR in perioperative NSCLC, 84.6% ORR in MSS CRC, 72.4% ORR in TNBC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208357,"accession_number":"0001193125-24-217618","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics raises $235M in private placement led by insiders at $22.70/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 10.35M shares at $22.70, the closing price on Sept 11; aggregate gross proceeds ~$235M.","$79M raised from insiders including CEO Robert Duggan, Dr. Zanganeh, Soni, Anand, and director Jeff Huber.","Remaining $156M from multiple leading biopharma institutional investors; no bankers' fees.","Proceeds to advance ivonescimab clinical development in NSCLC and other cancers, plus working capital.","Company will file a resale registration statement with SEC after closing expected by Sept 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208356,"accession_number":"0001599298-24-000128","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Summit reports ivonescimab beats Keytruda in Phase 3 NSCLC trial; PFS HR=0.51 p<0.0001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ivonescimab vs pembrolizumab in 1L PD-L1+ advanced NSCLC: mPFS 11.14 vs 5.82 months (HR 0.51, p<0.0001).","ORR 50.0% vs 38.5%, DCR 89.9% vs 70.5%. OS not yet mature; safety manageable.","Subgroup benefit consistent: PD-L1 TPS≥50% HR 0.46; squamous HR 0.48; non-squamous HR 0.54.","Phase II perioperative AK112-205 in resectable NSCLC: MPR 71.8% (cohort 2), pCR 43.6% with ivonescimab+chemo.","Additional Phase II data in breast, colorectal, head & neck cancers released at ESMO; conference call Sep 9."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208355,"accession_number":"0001599298-24-000113","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics Q2 net loss $60.4M; ivonescimab achieves first Phase III win over Keytruda","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $60.4M ($0.09/sh) vs $14.7M ($0.02) in Q2 2023; non-GAAP loss $34.3M.","Cash $325.8M (up from $186.2M) after $200M June equity offering; runway into Q4 2025.","HARMONi-2: ivonescimab monotherapy beat pembrolizumab in 1L NSCLC, first drug to do so in Phase III.","HARMONi-A: ivonescimab+chemo reduced progression/death by 54% (HR 0.46) in EGFR-mutated NSCLC post-TKI.","Expanded license to Latin America, Middle East, Africa; five-year strategic collaboration with MD Anderson."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226026,"accession_number":"0001599298-24-000103","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Summit Therapeutics appoints Jeff Huber, ex-Google SVP and GRAIL co-founder, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Huber elected to Summit board effective June 27, 2024; will serve on Audit Committee.","Huber co-founded GRAIL and was SVP at Alphabet/Google; led Maps, Apps, and Ads development.","Huber received stock option grant and standard director compensation under company policy.","Board determined Huber qualifies as independent; no material related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226025,"accession_number":"0001193125-24-162715","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Summit Therapeutics director Ujwala Mahatme resigns; annual meeting elects all eight nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Ujwala Mahatme resigned effective June 12, 2024, to focus on professional commitments; no disagreement with company.","At June 14 annual meeting, all eight director nominees elected with large majorities (e.g., Robert W. Duggan received 620.6M votes).","Stockholders ratified PwC as independent auditor for FY 2024 with 639.3M votes for and 39.8K against.","Non-binding advisory vote on executive compensation passed with 604.2M for, 15.9M against, and 18.9M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226024,"accession_number":"0001193125-24-152309","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Summit raises $200M, expands ivonescimab license to LAMEA regions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $200M via private placement of 22.2M shares at $9.00/share, a premium to the prior close.","Expanded ivonescimab license territory to Latin America, Middle East, Africa; $15M upfront plus up to $55M milestones.","Net proceeds will fund ivonescimab clinical development and general corporate purposes.","Registration rights agreement filed; resale registration statement expected within 60 days of closing.","Amendment strengthens data-sharing provisions for global ivonescimab trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226023,"accession_number":"0001193125-24-152292","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ivonescimab plus chemo gets NMPA approval in China for EGFRm NSCLC; PFS HR 0.46 in HARMONi-A","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NMPA approved ivonescimab + chemo for 2L+ EGFR-mutant non-squamous NSCLC based on HARMONi-A Phase III trial sponsored by Akeso.","PFS hazard ratio 0.46 (p<0.001); median PFS 7.1 months vs 4.8 months for placebo + chemo.","ORR 50.6% vs 35.4% and DCR 93.1% vs 83.2%; OS trended positive (HR 0.72 at 10.2 mo follow-up).","Subgroup with 3rd-gen TKI: PFS HR 0.48; safety manageable — 5.6% discontinued ivonescimab due to TRAEs.","Multi-regional HARMONi trial (target 420 patients) enrolling; completion expected in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226022,"accession_number":"0001599298-24-000096","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Summit: Ivonescimab beats pembrolizumab in Phase III HARMONi-2 for PD-L1+ NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ivonescimab met primary endpoint PFS with statistically significant and clinically meaningful superiority over pembrolizumab.","Benefit observed across subgroups: PD-L1 low/high, squamous/non-squamous, and high-risk patients.","First drug to show statistically significant superiority over pembrolizumab in a head-to-head Phase III NSCLC trial.","Full data set to be presented at upcoming major medical conference; conference call June 3 at 8am ET.","Summit plans to expand development of ivonescimab into other tumors beyond NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226021,"accession_number":"0001599298-24-000092","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Summit partner Akeso wins China NMPA approval for ivonescimab in EGFR-mutated NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NMPA approved ivonescimab + chemo for EGFR-mutated advanced non-squamous NSCLC after TKI failure.","First regulatory approval for ivonescimab globally; based on HARMONi-A Phase III trial.","Median PFS by IRRC: 7.06 mo (ivonescimab) vs 4.80 mo (chemo alone); HR 0.46 (95% CI 0.34-0.62).","Grade ≥3 TEAEs: 61.5% in ivonescimab arm vs 49.1% in chemo arm; mostly chemo-related.","Approval does not affect Summit's US/global development plan; HARMONi and HARMONi-3 trials continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226020,"accession_number":"0001599298-24-000089","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Summit Therapeutics enters $90M ATM equity distribution agreement with JPMorgan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $90M of common stock may be sold at-the-market through J.P. Morgan Securities LLC as sales agent.","Company has no obligation to sell any shares; sales at prevailing market prices or negotiated prices.","Sales agent commission is up to 3.0% of gross proceeds per share sold.","Offerings made under existing S-3 shelf registration (File No. 333-277169) declared effective Feb 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226019,"accession_number":"0001599298-24-000087","cik":1599298,"company_name":"Summit Therapeutics Inc.","ticker":"SMMT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Summit Therapeutics Q1 net loss $43.5M; cash $157M; ivonescimab shows 34% intracranial response in NSCLC brain mets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $43.5M ($0.06/sh) vs $542.3M ($1.43/sh) prior year; non-GAAP net loss $34.0M ($0.05/sh).","Cash and investments $157M at March 31; operating cash outflow $30.1M; guidance cash runway through Q1 2025.","R&D expenses $30.9M GAAP, up from $9.9M; non-GAAP R&D $28.5M as trial enrollment expands.","Ivonescimab Phase II data: 34% intracranial response rate; median intracranial PFS 19.3 months in NSCLC brain metastases; mPFS 11.1 months in first-line squamous NSCLC.","HARMONi (EGFR-mutant NSCLC) enrollment completion expected H2 2024; HARMONi-3 (first-line squamous) first patient treated Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13381043654.00691,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}